STAGE IVA BLADDER CANCER AJCC V8
Clinical trials for STAGE IVA BLADDER CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IVA BLADDER CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IVA BLADDER CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Bladder cancer drug combo study halted before enrolling any patients
Disease control TerminatedThis study was designed for people with muscle-invasive bladder cancer who cannot take the standard chemotherapy drug cisplatin. It aimed to compare a targeted therapy (erdafitinib) alone versus the same drug combined with an immunotherapy (atezolizumab) to see if these treatment…
Matched conditions: STAGE IVA BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 01, 2026 15:59 UTC
-
Immunotherapy plus chemo shows promise for Tough-to-Treat cancers
Disease control OngoingThis early-stage trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can help people with rare, aggressive small cell or neuroendocrine cancers of the bladder or prostate. About 15 adults whose cancer has spread will receive the combination. T…
Matched conditions: STAGE IVA BLADDER CANCER AJCC V8
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC